MIRATI: Phase 2 Trial of MRTX849 Monotherapy and in Combination With Pembrolizumab in patients with advanced Non-Small Cell Lung Cancer with KRAS G12C Mutation
Treatment study for advances metastatic cancer with KRAS G12C mutation
The phase 2 portion of “MIRATI” is a clinical study for patients with locally advanced non-small cell lung cancer that have the KRAS G12C mutation. The goal of this study is to evaluate safety and efficacy of the investigational MRTX849 monotherapy, in combination with KEYTRUDA, as a potential first-line treatment for this type of lung cancer.
For more information, please contact
Juanita Johnson, Juanita.Johnson2@va.gov, 786-299-0175
